Atai Life Sciences

Last updated
Atai Life Sciences
NASDAQ: ATAI
Industry Pharmaceutical; Psychedelic medicine
Founded2018;7 years ago (2018)
Headquarters
Berlin
,
Germany
Key people
Christian Angermayer, Florian Brand, Lars Christian Wilde, Srinivas Rao
Website atai Life Sciences

atai Life Sciences is a pharmaceutical company that is developing psychedelics, other hallucinogens, entactogens, and related drugs for treatment of psychiatric conditions. [1] [2] [3] [4] [5] It was founded in 2018 and is headquartered in Berlin, Germany. [1] [5]

The company's pharmaceutical candidates include dimethyltryptamine (DMT; VLS-01), (R)-midomafetamine ((R)-MDMA; EMP-01), and ibogaine (IBX-210, DMX-1002), as well as EGX-121 (a non-tryptamine new chemical entity), 5-MeO-DMT (BPL-003), psilocin (ELE-101), inidascamine (RL-007), deuterated mitragynine (KUR-101), EGX-A, EGX-B, deuterated etifoxine (GRX-917), and arketamine (PCN-101). [4] [3] [6]

In June 2021, atai became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. [1] [7] In January 2023, atai Life Science's leading drug candidate at the time, arketamine (PCN-101), failed to meet its primary endpoint in a clinical trial. [1] Following that, the company laid off 30% of its staff. [1]

Peter Thiel is a major investor in the company. [1] atai Life Sciences has a 22.4% stake in Compass Pathways. [1] [5]

References

  1. 1 2 3 4 5 6 7 Aday, Jacob S.; Barnett, Brian S.; Grossman, Dan; Murnane, Kevin S.; Nichols, Charles D.; Hendricks, Peter S. (1 September 2023). "Psychedelic Commercialization: A Wide-Spanning Overview of the Emerging Psychedelic Industry" (PDF). Psychedelic Medicine. 1 (3): 150–165. doi:10.1089/psymed.2023.0013. ISSN   2831-4425.
  2. ↑ Grinstein, Jonathan D. (7 April 2023). "Go Higher: Atai Life Sciences Is Moving the Dial on Psychedelic Medicine Clinical Trial Outcomes". GEN - Genetic Engineering and Biotechnology News. Retrieved 27 February 2025.
  3. 1 2 "Delving into the Latest Updates on ATAI Life Sciences AG with Synapse". Synapse. 23 January 2025. Retrieved 27 February 2025.
  4. 1 2 "Psychedelics Drug Development Tracker". Psychedelic Alpha. Retrieved 27 February 2025.
  5. 1 2 3 "ATAI Life Sciences". Psychedelic Alpha. 6 October 2023. Retrieved 27 February 2025.
  6. ↑ "Programs". atai Life Sciences. 13 January 2025. Retrieved 27 February 2025.
  7. ↑ Ponieman, Natan (14 June 2021). "Psyched: Atai's $214M IPO, MindMed CEO Resigns, Field Trip Applies To Nasdaq, Cybin And Novamind Target Frontline Health Workers". finance.yahoo.com. Retrieved 2021-06-24.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.